![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rexahn Pharmaceuticals Inc | NASDAQ:REXN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.81 | 1.75 | 1.83 | 0 | 01:00:00 |
Delaware
|
11-3516358
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number.)
|
37000 Grand River Avenue, Suite 120
|
|
|
Farmington Hills, MI | 48335 | |
(Address of principal executive offices)
|
(Zip code)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
Item 3. |
Incorporation of Documents By Reference.
|
(a) |
the Registrant’s Annual Report on Form 10-K filed on March 30, 2023;
|
(b) |
the Registrant’s Current Report on Form 8-K filed on January 25, 2023;
|
(c) |
the description of the Company’s Common Stock contained in the Company’s Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), on May 23, 2008.
|
Item 8. |
Exhibits.
|
Exhibit
Number
|
Description
|
|
Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix G to the Company’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2005)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on May 5, 2017)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on August 30, 2018)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on April 12, 2019).
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K, filed on November 6, 2020)
|
||
First Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on June 10, 2022)
|
||
Second Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on June 17, 2022)
|
||
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Company’s Registration Statement on Form S-4, filed on September 30, 2020)
|
||
Opinion of Honigman LLP
|
||
Consent of Ernst & Young LLP
|
||
Consent of Honigman LLP (included in Exhibit 5.1)
|
||
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
|
||
Filing Fee Table
|
OCUPHIRE PHARMA, INC.
|
|||
By:
|
/s/ Mina Sooch
|
||
Name:
|
Mina Sooch
|
||
Title:
|
President and Chief Executive Officer
|
SIGNATURE
|
TITLE
|
DATE
|
||
/s/ Mina Sooch
|
||||
Mina Sooch
|
President, Chief Executive Officer & Director
(Principal Executive Officer)
|
April 5, 2023
|
||
/s/ Amy Rabourn
|
||||
Amy Rabourn
|
Senior Vice President of Finance
(Principal Financial and Accounting Officer)
|
April 5, 2023
|
||
/s/ Sean Ainsworth
|
||||
Sean Ainsworth
|
Director
|
April 5, 2023
|
||
/s/ James S. Manuso
|
||||
James S. Manuso
|
Director
|
April 5, 2023
|
||
/s/ Cam Gallagher
|
||||
Cam Gallagher
|
Director
|
April 5, 2023
|
||
/s/ Jay Pepose
|
||||
Jay Pepose
|
Director
|
April 5, 2023
|
/s/ Richard Rodgers
|
||||
Richard Rodgers
|
Director
|
April 5, 2023
|
||
/s/ Susan K. Benton
|
||||
Susan K. Benton
|
Director
|
April 5, 2023
|
1 Year Rexahn Pharmaceuticals Chart |
1 Month Rexahn Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions